RGEN REPLIGEN CORP Insider Trading

CEO Loeillot Olivier sold 3,832 shares of RGEN at $140.00 (-27.8% from 52-week high); stock now $124.40

Loeillot Olivier, CEO of Repligen, sold 3,832 shares at $140.00 on 2026-04-21, reducing holdings by 6.6% to 54,246 shares post-transaction. The sale occurred 27.8% below the 52-week high of $172.26, following a 25.9% decline over the prior 90 days. His cross-ticker track record shows 1 prior sell with a 100% well-timed rate (average 90d return -20.4%), and his prior RGEN sale on 2025-11-25 demonstrated the same pattern. The company reports strong fundamentals with annual revenue growth of 16.4%, $188.8M latest-quarter revenue, and $14.9M net income; however, the P/E of 92.15 remains elevated relative to recent price momentum. Current price of $124.40 indicates the stock has fallen further since the transaction, consistent with the insider's historical sell-timing pattern.

CEO Loeillot Olivier sold 7,041 shares of RGEN at $170.00 for $1.2M; holds 35.9K post-transaction.

CEO Loeillot Olivier sold 7,041 shares (7.0K shares) at $170.00, reducing his stake from 42,939 shares to 35,898 shares (a -16.4% reduction in holdings). The transaction occurred at a price near the 52-week high of $174.24, within 1.8% of that peak. REPLIGEN's fundamentals present a mixed picture: while recent quarterly revenue stands at $188,805,000.00 and the company generated $14,911,000.00 in net income last quarter, full-year profitability was negative and annual revenue growth was -0.7%. The elevated P/E of 5706.00 reflects the company's recent unprofitability on a full-year basis. The sale occurs amid strong 90-day momentum (+40.1%) and 30-day strength (+6.3%), yet the CEO's decision to reduce exposure by 16.4% of his holdings at near-peak valuation deserves attention given the company's deteriorating annual profitability metrics and negative revenue growth trajectory.

Director Hunt Anthony sells 20,000 shares (20.0K) at blended $154.61 for $3.1M; 5 similar sales on 2025-11-12; RGEN at depressed valuation (P/E: 5079.00).

Hunt Anthony executed 7 separate sales totaling 20,000 shares for $3,092,278.36 on 2025-11-13, reducing his holdings by 19.3% to 83,695 shares. This follows 5 prior sales on 2025-11-12, indicating a concentrated two-day liquidation pattern. The blended average sale price of $154.61 is above the current price of $152.37, though the stock remains within its 52-week range (-12.6% from the $174.24 high) and up 22.5% over 90 days. RGEN's fundamentals present a warning: the company reported a negative full-year net income despite $188.8M in quarterly revenue, and its P/E of 5079.00 reflects minimal profitability. Across his cross-ticker track record, Hunt's 20 prior sells averaged -6.0% 90-day returns with a 44.44% well-timed rate; no measurable outcomes yet exist for his 5 prior RGEN trades on 2025-11-12. The scale and timing of this director-level liquidation warrants monitoring given the company's unprofitable status and elevated valuation metrics.

Director Hunt Anthony sells 25,000 RGEN shares across 5 transactions on 2025-11-12 for $3.9M at avg $156.88

Hunt Anthony, a director at Repligen, executed 5 separate sales totaling 25,000 shares for $3,921,939.67 on 2025-11-12, reducing his holdings by -19.9% from 125,743 to 100,743 shares. The sales occurred at prices ranging from $154.92 to $158.51, above the current price of $150.56 and well above the 52-week low of $108.89, positioning the exit in the upper range of recent valuations. The company carries significant valuation stress: its P/E ratio of 5018.67 reflects near-zero profitability (net income of $14,911,000 on $188.8M quarterly revenue), and it was unprofitable over the most recent full fiscal year, indicating fundamental challenges beyond this single trading event. His cross-ticker track record shows a 28.57% well-timed rate on prior sells (negative 90d average return of -3.3%), but this is his first measurable sale at RGEN, so same-ticker precedent is absent.

Director Hunt Anthony sold 29,111 shares at $120.52 avg for $3.5M on 2025-09-10

Hunt Anthony, a Director at Repligen Corp, executed 6 separate sales totaling 29,111 shares for $3,508,388.91 on 2025-09-10, reducing his holdings by 22.4% from 129.9K to 100.7K shares. The blended average sale price of $120.52 sits within the 52-week range but 31.4% below the 52-week high of $174.24, reflecting the stock's recent weakness (down 6.3% over 90 days and 1.6% over 30 days). His cross-ticker track record shows a 47.37% well-timed rate on 19 prior sells, but at Repligen specifically, 0 of 5 prior sales (all on 2025-05-15) were well-timed at the 90-day mark. The sale occurs as the company reported annual revenue growth of -0.7% and full-year net income was negative, signaling operational headwinds that warrant investor attention.

Director Martin D Madaus buys 1,800 shares of RGEN at $112.13; prior 5 trades at RGEN all well-timed at 90d mark (win rate 100%)

Director Martin D Madaus purchased 1,800 shares at $112.13, establishing an initial position in REPLIGEN CORP. This marks his fifth purchase at this ticker since May 2023, and notably his prior trades at RGEN demonstrated perfect timing discipline: all 5 prior buys were well-timed at the 90-day mark, with a 100% win rate and cumulative 90-day returns ranging from +5.8% to +14.0%. His cross-ticker track record shows 7 prior open-market buys with an average 90-day return of +12.0% and a 100% 90-day win rate. Against current price ($121.40), he is down approximately 8% from entry, and the stock trades -30.3% below its 52-week high. While REPLIGEN's fundamentals show flat revenue growth (-0.7% YoY) and recent full-year unprofitability, the insider's consistent repurchasing pattern at this ticker—especially with zero timing missteps across five prior acquisitions—suggests sustained conviction in accumulation despite near-term price weakness.

Director Hunt Anthony sold 26,447 shares (26.4K) for $3,271,687.92 in 5 separate sales on 2025-05-15 at $122.66–$127.00; stock down -4.2% (30d), -13.9% (90d) from transaction date.

Hunt Anthony, Director at Repligen Corp, executed 5 separate sales totaling 26.4K shares for $3.3M, reducing his holdings by -19.4% (from 136.3K to 109.9K shares). His cross-ticker track record shows 19 prior sells with a 61.54% well-timed rate and average 90-day returns of -5.4%, indicating modest historical accuracy in sell timing. However, at RGEN specifically, all 5 of his prior measurable trades (conducted 2025-03-17) showed negative 30-day returns ranging -10.8% to -14.0%, with none yet measurable at 90 days. The company reported full-year net loss (unprofitable) and negative revenue growth of -0.7%, while trading -28.1% below its 52-week high, providing a backdrop of financial underperformance. The timing and volume of this liquidation warrant scrutiny given the broader fundamental and technical weakness in the name.

Director Hunt Anthony sells 26,756 shares of RGEN for $4.1M across 6 transactions on 2025-03-17

Hunt Anthony, a Director, executed 6 separate sales totaling 26,756 shares for $4,080,663.26 on 2025-03-17, reducing his holdings by 16.4% to 136,301 shares at a blended average price of $152.51. The current stock price of $144.88 is 27.5% below the 52-week high of $199.74, and the company reported negative net income of $-654,000.00 for the latest quarter with annual revenue declining 0.7% year-over-year. At this specific ticker (RGEN), Anthony's prior 5 sales show no well-timed 90-day outcomes, with all 5 prior sells followed by positive 90-day returns, yet this large stake reduction occurs as the stock trades significantly below its 52-week peak.

Director Pax Margaret bought 250 RGEN shares at $150.69; holdings now 1,043 shares (+31.5%)

Pax Margaret (Director) purchased 250 shares at $150.69 on 2025-03-17, increasing her position by 31.5% to 1,043 total shares. The transaction occurred when the stock was trading 27.7% below its 52-week high of $199.74, having declined 1.8% over the prior 30 days. However, context tempers any interpretation: REPLIGEN's most recent fiscal year ended with negative net income (full-year net income was negative), and the company reported a net loss of $-654.0K in its latest quarter against revenue of $154.9M, suggesting operational strain. Annual revenue growth was flat at -0.7% versus the prior year. Without FLAGS or TRACK RECORD data indicating this purchase was pre-scheduled, the buy at a price materially below the 52-week high occurs at a moment when the company's profitability picture remains challenged.

Director Hunt Anthony sold 24,246 shares of RGEN for $3.4M at $139.67; stock down -31.6% from 52-week high amid -20.3% annual revenue decline.

Hunt Anthony, a director at Repligen Corp, sold 24,246 shares for $3,386,438.82 at $139.67 on 2024-11-21, reducing his position by 14.8% from 164,086 to 139,840 shares. The sale occurs in the context of weak fundamentals: the company reported revenue of $154,871,000.00 in the latest quarter with net loss of $-654,000.00, and annual revenue contracted 20.3% year-over-year. The stock is trading at $142.58 (current), representing a -31.6% decline from its 52-week high of $208.42. Anthony's cross-ticker track record shows a 100% win rate on his 18 prior sales with an average 90-day return of -18.3%, indicating consistent execution in selling before declines; his same-ticker history shows four prior sales on 2024-09-10 that declined 6.4% to 8.3% over 30 days. This sale extends a pattern of director liquidity at depressed valuations relative to recent highs.